Rapid development of a registry to accelerate COVID-19 vaccine clinical trials

被引：0

作者：

Neil F. Abernethy ^{[1
]}

Kylie McCloskey ^{[2
]}

Meg Trahey ^{[2
]}

Laurie Rinn ^{[2
]}

Gail Broder ^{[2
]}

Michele Andrasik ^{[2
]}

Rebecca Laborde ^{[3
]}

Daniel McGhan ^{[3
]}

Scott Spendolini ^{[3
]}

Senthil Marimuthu ^{[3
]}

Adam Kanzmeier ^{[3
]}

Jayson Hanes ^{[3
]}

James G. Kublin ^{[2
]}

机构：

[1] University of Washington,Biomedical Informatics and Medical Education

[2] Fred Hutchinson Cancer Center,HIV Vaccine Trials Network (HVTN), COVID

[3] Oracle Corporation,19 Prevention Network (CoVPN)

来源：

npj Digital Medicine | / 8卷 / 1期

关键词：

D O I：

10.1038/s41746-025-01666-3

中图分类号：

学科分类号：

摘要：

Response to the SARS-Cov-2 pandemic required the unprecedented, rapid activation of the COVID-19 Prevention Network (CoVPN) representing hundreds of sites conducting vaccine clinical trials. The CoVPN Volunteer Screening Registry (VSR) collected participant information, distributed qualified candidates across sites, and monitored enrollment progress. The system consisted of three web-based interfaces. The Volunteer Questionnaire flowed into a secure database. The Site Portal supported volunteer selection, analytics, and enrollment. The Administrative Portal enabled dynamic analytic reports by geography, clinical trial, and site, including volunteering rates over time. The VSR collected over 650,000 volunteers, serving a key role in the recruitment of diverse participants for multiple Phase 3 clinical trials. Over 47% of the 166,729 volunteers selected for screening represented prioritized groups. The success of the VSR demonstrates how digital tools can be rapidly yet safely integrated into an accelerated clinical trial setting. We summarize the development of the system and lessons learned for pandemic preparedness.

引用